Boston Scientific Co. (NYSE:BSX) EVP Sells $685,244.16 in Stock

Boston Scientific Co. (NYSE:BSX) EVP John Bradley Sorenson sold 6,528 shares of the company’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $104.97, for a total value of $685,244.16. Following the sale, the executive vice president now owns 26,449 shares in the company, valued at approximately $2,776,351.53. This trade represents a 19.80 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

John Bradley Sorenson also recently made the following trade(s):

• On Thursday, January 2nd, John Bradley Sorenson sold 4,119 shares of Boston Scientific stock. The shares were sold at an average price of $90.02, for a total value of $370,792.38.

Boston Scientific Trading Down 0.1 %

Shares of NYSE:BSX opened at $106.03 on Wednesday. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $156.26 billion, a PE ratio of 84.82, a P/E/G ratio of 2.79 and a beta of 0.80. Boston Scientific Co. has a 12-month low of $64.54 and a 12-month high of $107.17. The business’s fifty day simple moving average is $95.19 and its 200-day simple moving average is $87.50.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. As a group, equities research analysts predict that Boston Scientific Co. will post 2.83 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on BSX. Raymond James boosted their price objective on shares of Boston Scientific from $119.00 to $122.00 and gave the company a “strong-buy” rating in a research report on Thursday, February 6th. StockNews.com upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a report on Wednesday, January 29th. TD Cowen raised their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, December 12th. UBS Group upped their target price on Boston Scientific from $105.00 to $130.00 and gave the company a “buy” rating in a research note on Friday, February 7th. Finally, Deutsche Bank Aktiengesellschaft raised Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a research note on Friday, January 10th. One investment analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $107.39.

Institutional Investors Weigh In On Boston Scientific

Several institutional investors have recently bought and sold shares of BSX. Ritholtz Wealth Management boosted its position in shares of Boston Scientific by 22.8% in the 3rd quarter. Ritholtz Wealth Management now owns 28,596 shares of the medical equipment provider’s stock worth $2,396,000 after purchasing an additional 5,303 shares in the last quarter. CRA Financial Services LLC boosted its holdings in Boston Scientific by 4.3% in the third quarter. CRA Financial Services LLC now owns 2,841 shares of the medical equipment provider’s stock worth $238,000 after acquiring an additional 117 shares in the last quarter. CHICAGO TRUST Co NA grew its stake in shares of Boston Scientific by 6.0% during the third quarter. CHICAGO TRUST Co NA now owns 31,216 shares of the medical equipment provider’s stock worth $2,616,000 after acquiring an additional 1,777 shares during the last quarter. Compagnie Lombard Odier SCmA increased its holdings in shares of Boston Scientific by 280.4% during the third quarter. Compagnie Lombard Odier SCmA now owns 3,100 shares of the medical equipment provider’s stock valued at $260,000 after acquiring an additional 2,285 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. raised its position in shares of Boston Scientific by 32.4% in the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 3,786 shares of the medical equipment provider’s stock valued at $317,000 after purchasing an additional 927 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.